Abstract
Androgen deprivation therapy (ADT) for prostate cancer (PCa) causes bone loss. Although we reported previously that risedronate significantly recovers bone mineral density (BMD) for up to 12 months, there have been no reports with longer follow-up periods to date. This study extended our earlier series extending the follow-up period to 24 months. Eligible patients had histologically confirmed PCa without lumbar spine metastasis and underwent ADT. Lumbar spine BMD, urinary deoxypyridinoline (uDPD) and serum bone alkaline phosphatase were measured at 6, 12 and 24 months. Among the total of 96 patients, we analyzed 26 and 18 patients in risedronate administration and control groups, respectively. BMD relative to the young adult mean ratio, uDPD and serum bone alkaline phosphatase of the risedronate administration group recovered significantly after 24 months compared with the control group (P<0.0001, P=0.0001, and P<0.0001, respectively). Transient blurred vision, malaise and vertigo were observed in 1 patient each among the 46 patients treated with risedronate within 28 days after first administration. Oral administration of risedronate is safe and effective for the recovery of ADT-induced bone loss in PCa patients even at 24 months after commencement of treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ferlay J, Parkin DM, Steliarova-Foucher E . Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765–781.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–249.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T et al. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol 2006; 176: S47–S49.
Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR . Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006; 106: 1708–1714.
Smith MR . Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007; 14: 247–254.
Holzbeierlein JM, Castle EP, Thrasher JB . Complications of androgen-deprivation therapy for prostate cancer. Clin Prostate Cancer 2003; 2: 147–152.
Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miwa S, Maeda Y et al. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 2009; 73: 1342–1346.
Labrie F, Cusan L, Gomez JL, Belanger A, Candas B . Long-term combined androgen blockade alone for localized prostate cancer. Mol Urol 1999; 3: 217–226.
Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujisawa S, Shiraki M et al. Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001; 19: 331–337.
Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT . Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181–186.
Morote J, Martinez E, Trilla E, Esquena S, Abascal JM, Encabo G et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 2003; 44: 661–665.
Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004; 101: 541–549.
Lipton A . Toward new horizons: the future of bisphosphonate therapy. Oncologist 2004; 9 (Suppl 4): 38–47.
Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948–955.
Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008–2012.
Saad F, Abrahamsson PA, Miller K . Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates. BJU Int 2009; 104: 1573–1579.
Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K . Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol 2007; 14: 1071–1075.
Taxel P, Dowsett R, Richter L, Fall P, Klepinger A, Albertsen P . Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int 2010; 106: 1473–1476.
Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol 2008; 26: 4426–4434.
Michaud LB, Goodin S . Cancer-treatment-induced bone loss, part 2. Am J Health Syst Pharm 2006; 63: 534–546.
Greenspan SL, Nelson JB, Trump DL, Resnick NM . Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416–424.
Michaud LB, Goodin S . Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm 2006; 63: 419–430.
Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P . A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548–1558.
Kaufman JM, Johnell O, Abadie E, Adami S, Audran M, Avouac B et al. Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 2000; 59: 765–772.
Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34: 195–202.
Delmas PD, Benhamou CL, Man Z, Tlustochowicz W, Matzkin E, Eusebio R et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 2008; 19: 1039–1045.
Moro-Alvarez MJ, DÃaz-Curiel M . Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis. Clin Interv Aging 2008; 3: 227–232.
Acknowledgements
We thank Maki Morita for data collection.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Izumi, K., Mizokami, A., Sugimoto, K. et al. Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study. Prostate Cancer Prostatic Dis 14, 238–242 (2011). https://doi.org/10.1038/pcan.2011.10
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2011.10
Keywords
This article is cited by
-
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis
Journal of Endocrinological Investigation (2016)
-
Osteoporose beim Mann mit hormonablativer Therapie bei nicht-metastasiertem Prostatakarzinom
Wiener Medizinische Wochenschrift (2012)